Respiratory viruses are increasingly recognized as a cause of pneumonitis following haematopoietic stem cell transplantation (HSCT). However, frequently, no pathogen is identified in cases of suspected viral pneumonia. Recently, a previously undescribed paramyxovirus, designated 'human metapneumovirus' (hMPV), was isolated from children with respiratory illness. We have detected hMPV as the sole pathogen in the nasopharyngeal aspirate of an HSCT recipient who succumbed to progressive respiratory failure following an upper respiratory prodrome. This report highlights the importance of further studies to elucidate the role of hMPV in causing respiratory illnesses in the HSCT population.
Interstitial pneumonia remains an important cause of mortality following haematopoietic stem cell transplantation (HSCT). With better understanding and management of cytomegalovirus infections, community respiratory viruses account for most of these cases. The most common viruses detected are human respiratory syncytial virus (RSV) and parainfluenza viruses. They account for about 30% of the acute respiratory illnesses post transplant and 50% of them progress to pneumonia with 30-100% mortality, depending on the clinical setting. [1] [2] [3] However, a significant minority of HSCT recipients present with a clinical condition indistinguishable from respiratory illness caused by respiratory viruses, which cannot be attributed to a known pathogen. We have an ongoing surveillance programme for post-transplant respiratory virus infection and no aetiological agent is identified in 40% of upper respiratory illnesses and 30% of cases of suspected viral pneumonia. 2 Recently, a previously undescribed virus was isolated from children with RSV-like disease in the Netherlands. 4 This has been designated human metapneumovirus (hMPV) as it resembles avian pneumovirus (also known as turkey rhinotracheitis virus), in both gene order and sequence. 5 Preliminary data indicate that this newly described virus is found in about 10% of childhood lower respiratory disease cases in which no other virus was identified. HMPV has now also been identified in respiratory samples from individuals aged 2 months to 87 years with acute respiratory tract illness in Canada. 6 Little is known about the significance of this newly described pathogen in immunocompromised patients. Recently, fatal pneumonia owing to hMPV was described in a child on treatment for acute lymphoblastic leukaemia (ALL). 7 We describe the detection of hMPV for the first time in a fatal case of pneumonitis in an allogeneic HSCT patient and discuss the possible implications.
Case report
A 33-year-old lady with ALL received a T-cell-depleted peripheral blood stem cell graft (6 Â 10 6 /kg of CD 34+ cells) in August 2000, from her HLA-matched sibling, following conditioning with cyclophosphamide and total body irradiation. Cyclosporine A alone was used as graftversus-host disease (GVHD) prophylaxis. She had engraftment with donor cells by 14 days post transplant. She had a secondary graft failure 80 days after the transplant and received a second transplant (2.6 Â 10 6 /kg of CD 34+ cells) conditioned with ATG. However, she remained pancytopenic 21 days following this and received a further dose of donor cells (5.6 Â 10 6 /kg of CD 34+ cells) after conditioning with fludarabine and melphalan.
Seven days after her third transplant she developed pyrexia with cough and coryzal symptoms with negative microbial culture from blood, sputum, stool, urine and stool. She was initially treated with broad spectrum antibiotics. Amphotericin and clarithromycin were introduced 5 days later. The respiratory symptoms progressively worsened and the chest X-ray and CT scan showed both interstitial and alveolar opacities. A nasopharyngeal aspirate carried out at that stage (12 January 2001) was negative for RSV, influenza A and B, adenovirus and parainfluenza virus by direct immunoflorescence and culture. PCR assays for CMV were carried out on peripheral blood twice weekly and remained negative. She deteriorated progressively with worsening hypoxia and lung infiltrates coincident with recovery of the white cell count and was treated with a combination of imipenem, clarithromycin and ambisone. The patient refused any further intervention in the form of broncho-alveolar lavage (BAL) and ventilation. She succumbed to progressive respiratory failure on 17 January 2001. The family did not consent to a post-mortem examination.
Detection of hMPV: The stored nasopharyngeal aspirate taken 5 days before the demise of the patient was retrospectively examined for hMPV using RT-PCR and sequencing of PCR product undertaken as previously described. 4, 5 This was found to be positive for hMPV. Nucleotide sequence analysis of part of the fusion (F) gene of the virus from this patient showed that it was most closely related to the ned/00/01 strain previously described.
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Discussion
This patient presented with an upper respiratory prodrome and progressed to develop pneumonia and respiratory failure. Microbiological investigations for bacteria and viruses were consistently negative. Although the clinical features were compatible with a respiratory virus illness, the NPA sample was negative for the known viruses. Worsening of the respiratory illness in this patient was coincident with white cell recovery, compatible with the pattern noted with other respiratory viruses.
The detection of this newly identified respiratory virus, hMPV, in this patient is significant in that light and in the given clinical situation, hMPV can be considered as a possible aetiology for the respiratory illness. Whether or not hMPV was the cause of the respiratory symptoms cannot be definitively determined without demonstrating viral replication in the lung tissue and it is possible that the virus was simply an innocent bystander or a copathogen. A recent report implicated this virus in the causation of recurrent lower respiratory tract infections in a child with ALL. 7 In this case, hMPV was identified retrospectively and it was not demonstrable in the BAL specimen. However, the demonstration of hMPV in the NPA samples from both episodes in the absence of other isolates suggests that hMPV was probably the pathogen responsible for the fatal pneumonia in this child. Although this child was on intensive treatment and immunosuppressed, the immunodeficiency in allograft recipients is more severe and global. The similarities between this case 7 and our findings would warrant further investigation into the role of hMPV in respiratory illnesses following HSCT.
The implications of such a finding could be quite profound in the setting of HSCT. If hMPV is indeed a cause of lower respiratory infection in transplant recipients, further understanding of the epidemiology of this virus would be essential for the prevention of its spread within this vulnerable population, particularly within BMT units. Moreover, there might be a case for exploring the susceptibility of hMPV to antiviral agents such as ribavirin, both in vitro and in vivo.
